Renal Biomarker Market: Rising Prevalence of Renal Diseases Fuelling Demand for Renal Biomarkers: Global Industry Analysis and Opportunity Assessment, 2016-2026

Description:
Kidney diseases are one of the leading causes of death worldwide. The incidence of chronic kidney diseases is rapidly rising especially in the elderly population due to increase in life expectancy of general population and improvements in medical management services. However, diabetes and hypertension remain the leading cause of renal diseases.

Biomarkers are measurable indicators reflecting physiological and pharmacological progression of disease state. Recent advances in molecular biology have resulted in the development of novel biomarkers for the renal function. Extensive R&D by biomarker manufacturers has led to identification of novel renal biomarkers to deliver better diagnostic accuracy and improve patient outcomes.

Market Forecast

Revenue from the global renal biomarker market is projected to register a CAGR of 7.0% during the forecast period (2016 - 2026) and reach a market valuation of US$ 1,770.3 Mn by the end of 2026.

Rising prevalence of renal diseases primary driver boosting market growth.

Growth of the global renal biomarker market is mainly driven by rising prevalence of various renal diseases coupled with an ageing population worldwide. Also, there has been an increase in the adult population with chronic kidney diseases, primarily attributed to a rising prevalence of conditions such as diabetes and high blood pressure. Other prominent growth factors include large number of clinical trials in the novel renal biomarker and drug development space and penetration of various cost-effective, reliable, and rapid technologically driven diagnostic protocols in clinical practice. However, use of unreliable imperfect gold standard for renal disease diagnosis and lack of sensitivity and specificity in current renal biomarkers are some of the factors restraining the growth of the market over the forecast period.

Current trends governing the global renal biomarker market include the possible use of renal biomarkers in personalised medicine and drug development and a growing popularity of non-invasive renal biomarkers.

Market segmentation

By Biomarker Type
- Functional Biomarker
- Serum Creatinine
- Serum Cystatin C
- Urine Albumin
- Up-Regulated Proteins
- Neutrophil gelatinase-associated lipocalin
- Kidney injury molecule 1
- Interleukin 18
- Others

By Diagnostic Technique
- Enzyme Linked Immunosorbent Assay
- Particle-Enhanced Turbidimetric Immunoassay
- Colorimetric Assay
- Chemiluminescent Enzyme Immunoassay
- Liquid Chromatography-Mass Spectrometry

By End User
- Diagnostic Labs
- Outpatient Clinics
Functional Biomarker type segment expected to remain the dominant segment over the forecast period.

The Functional Biomarker segment is anticipated to account for a market value share of 52.3% by the end of 2016 and is expected to retain its dominance throughout the forecast period. The Up-Regulated Proteins segment is estimated to account for 33.8% market share in terms of value by 2016 end.

Enzyme Linked Immunosorbent Assay diagnostic technique segment estimated to hold the highest market share throughout the forecast period.

The Enzyme Linked Immunosorbent Assay segment is anticipated to register a CAGR of 8.1% over the forecast period and is expected to register high Y-o-Y growth rates from 2016 to 2026. The Particle-Enhanced Turbidimetric Immunoassay segment is estimated to be the second largest segment in terms of value, holding a market value share of 21.0% by 2016 end.

Diagnostic Labs end user segment expected to witness highest growth in terms of revenue throughout the forecast period.

The Diagnostic Labs segment is estimated to account for 34.2% market share of the global renal biomarker market in revenue terms by 2016 end and is expected to register high Y-o-Y growth rates throughout the forecast period. The Outpatient Clinics segment is anticipated to register a CAGR of 7.2% during the forecast period.

North America renal biomarker market expected to register high Y-o-Y growth throughout the forecast period.

The North America regional market is estimated to account for 32.2% revenue share of the global renal biomarker market by 2016 end. Western Europe is estimated to hold the second largest market share of 21.1% by 2016 end.

Leading market players are emphasising on product innovation and strategic acquisitions to increase market share.

Beckman Coulter, Inc. (Danaher Corporation), Thermo Fisher Scientific Inc., Abbott Laboratories, BIOPORTO A/S, Astute Medical, Inc., and Randox Laboratories Ltd. are some of the key players operating in the global renal biomarker market. Top market companies are focusing on increasing their presence in high-growth emerging markets through structured investments in R&D and technological innovation.
5.1. Introduction

6.1. Basis Point Share (BPS) Analysis
6.2. Yo-Yo Growth Projections
6.3. Market Value Forecast by Diagnostic Technique
6.4. Prominent Trends
6.5. Market Attractiveness

7.1. Introduction

8.1. Basis Point Share (BPS) Analysis
8.2. Yo-Yo Growth Projections
8.3. Market Value Forecast
8.4. Prominent Trends
8.5. Market Attractiveness

9.1. Introduction

10.1. Basis Point Share (BPS) Analysis
10.2. Yo-Yo Growth Projections
10.3. Market Value Forecast
10.4. Prominent Trends
10.5. Market Attractiveness

11.1. Introduction

12.1. Basis Point Share (BPS) Analysis
12.2. Yo-Yo Growth Projections
12.3. Market Value Forecast
12.4. Prominent Trends
12.5. Market Attractiveness
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis By Country
9.1.2. Y-o-Y Growth Projections By Country
9.1.3. Key Regulations
9.2. Market Value Forecast By Biomarker Type, 2015-2026
9.2.1. Functional Biomarker
  9.2.1.1. Serum Creatinine
  9.2.1.2. Serum Cystatin C
  9.2.1.3. Urine Albumin
9.2.2. Up-Regulated Proteins
  9.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
  9.2.2.2. Kidney Injury Molecule-1
  9.2.2.3. Interleukin-18
9.2.3. Others
9.3. Market Value Forecast By Diagnostic Technique, 2015-2026
  9.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
  9.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
  9.3.3. Colorimetric Assay
  9.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
  9.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
9.4. Market Value Forecast By End User, 2015-2026
  9.4.1. Diagnostic Labs
  9.4.2. Outpatient Clinics
  9.4.3. Research Centers
9.4.4. Hospitals
9.5. Market Value Forecast By Country, 2015-2026
  9.5.1. The U.S.
  9.5.2. Canada
9.6. Market Attractiveness Analysis
  9.6.1. By Biomarker Type
  9.6.2. By Diagnostic Technique
  9.6.3. By End User
  9.6.4. By Country
9.7. Prominent Trends
9.8. Drivers and Restraints: Impact Analysis

10. Latin America Renal Biomarker Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis By Country
10.1.2. Y-o-Y Growth Projections By Country
10.1.3. Key Regulations
10.2. Market Value Forecast By Biomarker Type, 2015-2026
  10.2.1. Functional Biomarker
  10.2.1.1. Serum Creatinine
  10.2.1.2. Serum Cystatin C
  10.2.1.3. Urine Albumin
  10.2.2. Up-Regulated Proteins
  10.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
  10.2.2.2. Kidney Injury Molecule-1
  10.2.2.3. Interleukin-18
  10.2.3. Others
10.3. Market Value Forecast By Diagnostic Technique, 2015-2026
  10.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
  10.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
  10.3.3. Colorimetric Assay
  10.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
  10.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
10.4. Market Value Forecast By End User, 2015-2026
10.4.1. Diagnostic Labs
10.4.2. Outpatient Clinics
10.4.3. Research Centers
10.4.4. Hospitals
10.5. Market Value Forecast By Country, 2015-2026
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6. Market Attractiveness Analysis
10.6.1. By Biomarker Type
10.6.2. By Diagnostic Technique
10.6.3. By End User
10.6.4. By Country
10.7. Prominent Trends
10.8. Drivers and Restraints: Impact Analysis

11. Western Europe Renal Biomarker Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis By Country
11.1.2. Y-o-Y Growth Projections By Country
11.1.3. Key Regulations
11.2. Market Value Forecast By Biomarker Type, 2015-2026
11.2.1. Functional Biomarker
11.2.1.1. Serum Creatinine
11.2.1.2. Serum Cystatin C
11.2.1.3. Urine Albumin
11.2.2. Up-Regulated Proteins
11.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
11.2.2.2. Kidney Injury Molecule-1
11.2.2.3. Interleukin-18
11.2.3. Others
11.3. Market Value Forecast By Diagnostic Technique, 2015-2026
11.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
11.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
11.3.3. Colorimetric Assay
11.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
11.3.5. Liquid Chromatography-Mass Spectrometry (LC-MS)
11.4. Market Value Forecast By End User, 2015-2026
11.4.1. Diagnostic Labs
11.4.2. Outpatient Clinics
11.4.3. Research Centers
11.4.4. Hospitals
11.5. Market Value Forecast By Country, 2015-2026
11.5.1. Germany
11.5.2. France
11.5.3. Italy
11.5.4. Spain
11.5.5. The U.K.
11.5.6. BENELUX
11.5.7. Rest of Western Europe
11.6. Market Attractiveness Analysis
11.6.1. By Biomarker Type
11.6.2. By Diagnostic Technique
11.6.3. By End User
11.6.4. By Country
11.7. Prominent Trends
11.8. Drivers and Restraints: Impact Analysis

12. Eastern Europe Renal Biomarker Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis By Country
12.1.2. Y-o-Y Growth Projections By Country
12.1.3. Key Regulations
12.2. Market Value Forecast By Biomarker Type, 2015-2026
12.2.1. Functional Biomarker
12.2.1.1. Serum Creatinine
12.2.1. Serum Cystatin C
12.2.1.3. Urine Albumin
12.2.2. Up-Regulated Proteins
12.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
12.2.2.2. Kidney Injury Molecule-1
12.2.2.3. Interleukin-18
12.2.3. Others
12.3. Market Value Forecast By Diagnostic Technique, 2015-2026
12.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
12.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
12.3.3. Colorimetric Assay
12.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
12.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
12.4. Market Value Forecast By End User, 2015-2026
12.4.1. Diagnostic Labs
12.4.2. Outpatient Clinics
12.4.3. Research Centers
12.4.4. Hospitals
12.5. Market Value Forecast By Country, 2015-2026
12.5.1. Russia
12.5.2. Poland
12.5.3. Rest of Eastern Europe
12.6. Market Attractiveness Analysis
12.6.1. By Biomarker Type
12.6.2. By Diagnostic Technique
12.6.3. By End User
12.6.4. By Country
12.7. Prominent Trends
12.8. Drivers and Restraints: Impact Analysis

13. Asia Pacific Excluding Japan (APEJ) Renal Biomarker Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis By Country
13.1.2. Y-o-Y Growth Projections By Country
13.1.3. Key Regulations
13.2. Market Value Forecast By Biomarker Type, 2015-2026
13.2.1. Functional Biomarker
13.2.1.1. Serum Creatinine
13.2.1.2. Serum Cystatin C
13.2.1.3. Urine Albumin
13.2.2. Up-Regulated Proteins
13.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
13.2.2.2. Kidney Injury Molecule-1
13.2.2.3. Interleukin-18
13.2.3. Others
13.3. Market Value Forecast By Diagnostic Technique, 2015-2026
13.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
13.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
13.3.3. Colorimetric Assay
13.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
13.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
13.4. Market Value Forecast By End User, 2015-2026
13.4.1. Diagnostic Labs
13.4.2. Outpatient Clinics
13.4.3. Research Centers
13.4.4. Hospitals
13.5. Market Value Forecast By Country, 2015-2026
13.5.1. China
13.5.2. India
13.5.3. ASEAN
13.5.4. Australia and New Zealand
13.5.5. Rest of APEJ
13.6. Market Attractiveness Analysis
13.6.1. By Biomarker Type
13.6.2. By Diagnostic Technique
13.6.3. By End User
13.6.4. By Country
13.7. Prominent Trends
13.8. Drivers and Restraints: Impact Analysis

14. Japan Renal Biomarker Market Analysis and Forecast
14.1. Introduction
14.1.1. Basis Point Share (BPS) Analysis By Country
14.1.2. Y-o-Y Growth Projections By Country
14.1.3. Key Regulations
14.2. Market Value Forecast By Biomarker Type, 2015-2026
14.2.1. Functional Biomarker
14.2.1.1. Serum Creatinine
14.2.1.2. Serum Cystatin C
14.2.1.3. Urine Albumin
14.2.2. Up-Regulated Proteins
14.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
14.2.2.2. Kidney Injury Molecule-1
14.2.2.3. Interleukin-18
14.2.3. Others
14.3. Market Value Forecast By Diagnostic Technique, 2015-2026
14.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
14.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
14.3.3. Colorimetric Assay
14.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
14.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
14.4. Market Value Forecast By End User, 2015-2026
14.4.1. Diagnostic Labs
14.4.2. Outpatient Clinics
14.4.3. Research Centers
14.4.4. Hospitals
14.5. Market Attractiveness Analysis
14.5.1. By Biomarker Type
14.5.2. By Diagnostic Technique
14.5.3. By End User
14.6. Prominent Trends
14.7. Drivers and Restraints: Impact Analysis

15. Middle East and Africa (MEA) Renal Biomarker Market Analysis and Forecast
15.1. Introduction
15.1.1. Basis Point Share (BPS) Analysis By Country
15.1.2. Y-o-Y Growth Projections By Country
15.1.3. Key Regulations
15.2. Market Value Forecast By Biomarker Type, 2015-2026
15.2.1. Functional Biomarker
15.2.1.1. Serum Creatinine
15.2.1.2. Serum Cystatin C
15.2.1.3. Urine Albumin
15.2.2. Up-Regulated Proteins
15.2.2.1. Neutrophil Gelatinase-Associated Lipocalin
15.2.2.2. Kidney Injury Molecule-1
15.2.2.3. Interleukin-18
15.2.3. Others
15.3. Market Value Forecast By Diagnostic Technique, 2015-2026
15.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
15.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
15.3.3. Colorimetric Assay
15.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
15.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)
15.4. Market Value Forecast By End User, 2015-2026
15.4.1. Diagnostic Labs
15.4.2. Outpatient Clinics
15.4.3. Research Centers
15.4.4. Hospitals
15.5. Market Value Forecast By Country, 2015-2026
15.5.1. GCC
15.5.2. South Africa
15.5.3. Rest of MEA
15.6. Market Attractiveness Analysis
15.6.1. By Biomarker Type
15.6.2. By Diagnostic Technique
15.6.3. By End User
15.6.4. By Country
15.7. Prominent Trends
15.8. Drivers and Restraints: Impact Analysis

16. Competition Landscape
16.1. Competition Dashboard
16.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
16.3.1. Beckman Coulter, Inc. (Danaher Corporation)
16.3.2. Thermo Fisher Scientific Inc.
16.3.3. Abbott Laboratories
16.3.4. BIOPORTO A/S
16.3.5. Astute Medical, Inc.
16.3.6. Randox Laboratories Ltd.

Ordering:
Order Online - http://www.researchandmarkets.com/reports/4031478/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Renal Biomarker Market: Rising Prevalence of Renal Diseases Fuelling Demand for Renal Biomarkers: Global Industry Analysis and Opportunity Assessment, 2016-2026
Web Address: http://www.researchandmarkets.com/reports/4031478/
Office Code: SC2GD2GC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Product Formats</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Electronic (PDF) -</td>
<td>USD 5000</td>
</tr>
<tr>
<td></td>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Electronic (PDF) -</td>
<td>USD 7500</td>
</tr>
<tr>
<td></td>
<td>Site License:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Electronic (PDF) -</td>
<td>USD 10000</td>
</tr>
<tr>
<td></td>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

| Account number | 833 130 83 |
| Sort code      | 98-53-30   |
| Swift code     | ULSBIE2D   |
| IBAN number    | IE78ULSB98533083313083 |
| Bank Address   | Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland. |

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World